Titian Software Expands US offices
News Oct 27, 2009
The move comes following continued company growth across Europe and the US, with 10 of the Top 20 pharma/biotech companies now using Titian’s Mosaic sample management software. The larger US premises will house sales and support activities of Titian Software US.
Richard Fry, Commercial Director of Titian commented, “The US has always been an important market for Titian and today approximately half our installations are in the States. I am therefore delighted, despite the current economic climate, to be able to further invest in the US to strengthen our local customer support.” He continued, “Relocation to larger premises gives us room to recruit additional staff in the US to meet current demand and maintain our high level of customer service.”
Titian Software develops software products and consultancy services for the life science industries, specialising in sample management for drug discovery research. Mosaic is Titian Software’s comprehensive, modular software product developed to control and monitor all aspects of sample storage and preparation. These include sample inventory tracking and ordering, workflow management, control of third party robotic equipment such as automated stores and liquid handlers, and integration with existing IT systems.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE